查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
mRNA疫苗和治疗药市场:2035年前的产业趋势和全球预测 - 各应用领域，各对象疾病，各地区
市场调查报告书
商品编码
1549410

mRNA疫苗和治疗药市场:2035年前的产业趋势和全球预测 - 各应用领域，各对象疾病，各地区

mRNA Vaccine and Therapeutics Market : Industry Trends and Global Forecasts, till 2035 - Distribution by Application Area, Target Disease Indication and Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 343 Pages | 商品交期: 最快1-2个工作天内

价格

到 2024 年，mRNA 疫苗和治疗药物市场规模预计将达到 90 亿美元，并预计在 2026-2035 年预测期内复合年增长率为 16%。

信使核糖核酸 (mRNA) 是单链核糖核酸 (RNA) 的一种形式，在传递蛋白质合成所需的遗传讯息方面发挥着重要作用。 mRNA 编码的蛋白质合成指令从 DNA 链转移到核醣体，并在核醣体中翻译成功能性蛋白质。 mRNA 疗法和疫苗的出现已成为传统疗法的革命性替代方案。 COVID-19大流行后，mRNA疗法和疫苗受到了广泛关注，是一类突破性药物，不仅可以治疗COVID-19，还可以治疗多种疾病，包括传染病、癌症和遗传性疾病。

迄今为止，四种基于 mRNA 的疫苗已被批准用于治疗 COVID-19，目前正在评估更多候选疫苗的治疗效果。基于 mRNA 的 COVID-19 疫苗和治疗方法的全面成功引起了许多投资者的兴趣，尤其是专注于 mRNA 技术的小型和新兴生物技术公司。

mRNA 疗法和疫苗的成就刺激了下一代 RNA 疗法市场研究活动的增加。基于 mRNA 的治疗药物和疫苗的强大产品线也正在推动 mRNA 合成和製造领域的成长，药物开发公司寻求合约服务来扩大基于 mRNA 的治疗药物的生产规模。

本报告提供全球mRNA疫苗和治疗药市场相关调查，提供市场概要，以及各应用领域，各对象疾病，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 调查手法

第3章 经济以及其他的计划特有的考虑事项

第4章 摘要整理

第5章 简介

第6章 市场形势

  • 章概要
  • mRNA疫苗与治疗药:市场形势

第7章 竞争情形

  • 章概要
  • mRNA疫苗与治疗药:开发商清单

第8章 企业竞争力分析

第9章 企业简介

第10章 大型製药公司的配合措施

第11章 Start-Ups的健全性指标

第12章 临床试验的分析

  • 章概要
  • 范围与调查手法
  • mRNA疫苗与治疗药:临床试验分析

第13章 伙伴关係和合作

第14章 资金筹措与投资分析

第15章 专利分析

第16章 对市场的影响分析:促进因素，阻碍因素，机会，课题

第17章 全球mRNA疫苗及治疗药市场

第18章 mRNA疫苗及治疗药市场(各应用领域)

第19章 mRNA疫苗及治疗药市场(各对象疾病)

第20章 mRNA疫苗及治疗药市场(各地区)

第21章 结论

Product Code: RA100390

The mRNA Vaccine and Therapeutics Market is valued at USD 9 billion in 2024 growing at a CAGR of 16% during the forecast period 2026-2035.

Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that plays a crucial role in transferring genetic information necessary for protein synthesis. The instructions encoded in mRNA for producing proteins are relayed from a DNA strand to ribosomes, where they are translated into functional proteins. The advent of mRNA therapeutics and vaccines has emerged as a groundbreaking alternative to traditional treatment methods. Following the COVID-19 pandemic, mRNA therapeutics and vaccines have gained substantial attention, establishing themselves as a revolutionary class of drugs for treating not only COVID-19 but also various other conditions, including infectious diseases, cancer, genetic disorders, and more.

To date, four mRNA-based vaccines have received approval for COVID-19 treatment, with numerous additional candidates currently undergoing evaluation as potential therapies. The overall success of mRNA-based vaccines and therapies against COVID-19 has piqued the interest of many investors, particularly in small and emerging biotechnology companies focused on mRNA technology.

The achievements in mRNA therapeutics and vaccines have spurred increased research activity in the next-generation RNA therapeutics market. A robust pipeline of mRNA-based therapeutics and vaccines is also propelling growth in the mRNA synthesis and manufacturing sector, as drug developers seek contract services to scale up the production of mRNA-based treatments.

Key Market Segments

Application Area

  • Covid-19
  • Other Indications

Target Disease Indication

  • Influenza
  • Respiratory Syncytial Virus Infection
  • Cytomegalovirus Diseases

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Rest of the World

Research Coverage:

  • A general introduction to mRNA, featuring insights on the historical evolution of mRNA therapeutics and vaccines. It also presents elaborate description on advantages associated with mRNA therapeutics and vaccines. It also features some of the key applications of both mRNA therapeutics and mRNA vaccines. Additionally, the chapter includes details on the various types of delivery routes and delivery strategies for mRNA drugs. Further, the chapter discusses the challenges associated with large scale adoption of mRNA therapeutics and vaccines and the associated future perspectives.
  • A detailed overview of the overall market landscape of mRNA therapeutics and vaccines, based on several relevant parameters, such as phase of development (marketed, phase III, phase II, phase I, preclinical and discovery), type of drug candidate (mRNA vaccine and mRNA therapeutic), therapeutic area (infectious diseases, oncological disorders, genetic disorders, neurological disorders, autoimmune disorders, pulmonary disorders and other therapeutic area), type of delivery system (lipid nanoparticles, lipopolyplex, liposomes, direct transfer, self-amplifying RNA platform and other delivery system), type of molecule encoded (spike protein, glycoprotein, protein coding gene, tumor neoantigen, cytokine, enzyme, tumor antigen, surface protein and other type of molecules) and route of administration (intramuscular, intravenous, intranasal and other routes of administration).
  • A detailed overview of the current market of players engaged in the development of mRNA vaccine and therapeutics, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters, regional landscape and key players engaged in this domain.
  • An in-depth company competitiveness analysis of players in mRNA vaccine and therapeutics domain, based on their developer strength (in terms of year of establishment and company size), pipeline strength (in terms of its pipeline maturity and drug administration route) and number of therapeutic areas targeted.
  • Elaborate profiles of key companies engaged in mRNA vaccine and therapeutics market. Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), financial information, mRNA vaccines and therapeutics pipeline, recent developments and an informed future outlook.
  • A review of the various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring a heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication being treated and focus therapeutic area), as well as a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
  • An analysis of start-ups (established since 2016) in this domain, based on several relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development. This chapter also provides details on amount raised, number of investors and number of deals inked.
  • An analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, therapeutic area, study design, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), enrolled patient population and geography.
  • An analysis of recent collaborations and partnerships within the mRNA therapeutics and vaccines industry, based on several relevant parameters, such as year of partnership, type of partnership, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, since 2013.
  • A detailed analysis of various investments made by players in this domain, since 2013, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings), amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).
  • An in-depth analysis of the various patents that have been filed / granted related to mRNA therapeutics and vaccines domain, since 2016, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical region, CPC symbols, leading industry players (in terms of the number of patents filed / granted) and patent valuation.
  • An in-depth analysis of the factors that can impact the growth of the market. It also features information on key drivers, potential restraints, emerging opportunities, and existing challenges within the mRNA vaccine and therapeutics market.
  • A detailed mRNA vaccine and therapeutics market forecast analysis with our estimates of the existing market size, market value and future opportunity for mRNA vaccine and therapeutics companies over the next 11 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market size during the forecast period 2024-2035.
  • Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different application area, such as Covid-19 and other indications.
  • Detailed projections of the current and future opportunity within the mRNA vaccines & therapeutics market across different target disease indication, such as influenza, respiratory syncytial virus infection and cytomegalovirus diseases.
  • Detailed projections of the current and future opportunity within the mRNA vaccine and therapeutics market across different geographical regions, such as North America, Europe, Asia-Pacific, Latin America and Rest of the World.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the mRNA Vaccine and Therapeutics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Arcturus Therapeutics
  • BioNTech
  • CureVac
  • Ethris

IMMORNA

  • Moderna
  • Providence Therapeutics
  • RNACure
  • Suzhou Abogen Biosciences
  • Turn Biotechnologies
  • Gennova
  • Innovac Therapeutics
  • Kernal Biologics
  • Pantherna Therapeutics
  • pHion Therapeutics
  • Recode Therapeutics
  • Rejuvenation Technologies
  • RNAimmune
  • Strand Therapeutics
  • Walvax
  • Ziphius Vaccines

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Research Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. mRNA Therapeutics
    • 5.2.1. Advantages of mRNA Therapeutics
    • 5.2.2. Key Applications of mRNA Therapeutics
  • 5.3. mRNA Vaccines
    • 5.3.1. Advantages of mRNA Vaccines
    • 5.3.2. Key Applications of mRNA Vaccines
  • 5.4. mRNA Delivery Routes
  • 5.5. mRNA Delivery Strategies
  • 5.6. Key Challenges Associated with mRNA Vaccine and Therapeutics
  • 5.7. Future Perspectives

6. MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. mRNA Vaccine and Therapeutics: Overall Market Landscape
    • 6.2.1. Analysis by Phase of Development
    • 6.2.2. Analysis by Type of Drug Candidate
    • 6.2.3. Analysis by Therapeutic Area
    • 6.2.4. Analysis by Phase of Development and Therapeutic Area
    • 6.2.5. Analysis by Type of Delivery System
    • 6.2.6. Analysis by Type of Molecule Encoded
    • 6.2.7. Analysis by Route of Administration
    • 6.2.8. Analysis by Therapeutic Area and Route of Administration
    • 6.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration

7. COMPETITIVE LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. mRNA Vaccine and Therapeutics: List of Developers
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Key Players: Analysis by Number of Drug Candidates
    • 7.2.5. Key Players: Analysis by Phase of Development
    • 7.2.6. Key Players: Analysis by Therapeutic Area

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Key Assumptions and Parameters
  • 8.3. Methodology
  • 8.4. mRNA Vaccine and Therapeutics Developers: Company Competitiveness Analysis
  • 8.5. mRNA Vaccine and Therapeutics Developers based in North America
  • 8.6. mRNA Vaccine and Therapeutics Developers based in Europe
  • 8.7. mRNA Vaccine and Therapeutics Developers based in Asia-Pacific and Rest of the World

9. COMPANY PROFILES

  • 9.1. Chapter Overview
  • 9.2. Leading Companies in mRNA Vaccine and Therapeutics Market
    • 9.2.1. Arcturus Therapeutics
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Financial Information
      • 9.2.1.3. Pipeline Overview
      • 9.2.1.4. Recent Developments and Future Outlook
    • 9.2.2. BioNTech
      • 9.2.2.1. Company Overview
      • 9.2.2.2. Financial Information
      • 9.2.2.3. Pipeline Overview
      • 9.2.2.4. Recent Developments and Future Outlook
    • 9.2.3. CureVac
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Financial Information
      • 9.2.3.3. Pipeline Overview
      • 9.2.3.4. Recent Developments and Future Outlook
    • 9.2.4. Ethris
      • 9.2.4.1. Company Overview
      • 9.2.4.2. Pipeline Overview
      • 9.2.4.3. Recent Developments and Future Outlook
    • 9.2.5. Immorna
      • 9.2.5.1. Company Overview
      • 9.2.5.2. Pipeline Overview
      • 9.2.5.3. Recent Developments and Future Outlook
    • 9.2.6. Moderna
      • 9.2.6.1. Company Overview
      • 9.2.6.2. Financial Information
      • 9.2.6.3. Pipeline Overview
      • 9.2.6.4. Recent Developments and Future Outlook
    • 9.2.7. Providence Therapeutics
      • 9.2.7.1. Company Overview
      • 9.2.7.2. Financial Information
      • 9.2.7.3. Pipeline Overview
      • 9.2.7.4. Recent Developments and Future Outlook
    • 9.2.8. Suzhou Abogen Biosciences
      • 9.2.8.1. Company Overview
      • 9.2.8.2. Pipeline Overview
      • 9.2.8.3. Recent Developments and Future Outlook
  • 9.3. Other Leading Players in mRNA Vaccine and Therapeutics Market
    • 9.3.1. Gennova Biopharmaceuticals
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Pipeline Overview
    • 9.3.2. Innovac Therapeutics
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Pipeline Overview
    • 9.3.3. Kernal Biologics
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Pipeline Overview
    • 9.3.4. Pantherna Therapeutics
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Pipeline Overview
    • 9.3.5. pHion Therapeutics
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Pipeline Overview
    • 9.3.6. Recode Therapeutics
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Pipeline Overview
    • 9.3.7. Rejuvenation Technologies
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Pipeline Overview
    • 9.3.8. RNACure
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Pipeline Overview
    • 9.3.9. RNAimmune
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Pipeline Overview
    • 9.3.10. Strand Therapeutics
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Pipeline Overview
    • 9.3.11. Turn Biotechnologies
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Pipeline Overview
    • 9.3.12. Walvax
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Pipeline Overview
    • 9.3.13. Ziphius Vaccines
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Pipeline Overview

10. BIG PHARMA INITIATIVES

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. mRNA Related Initiatives of Big Pharmaceutical Players
    • 10.3.1. Analysis by Portfolio Diversity
    • 10.3.2. Analysis by Phase of Development
    • 10.3.3. Analysis by Target Therapeutic Area
  • 10.4. Benchmarking Analysis: Big Pharma Players
    • 10.4.1. Spider Web Analysis: Amgen
    • 10.4.2. Spider Web Analysis: AstraZeneca
    • 10.4.3. Spider Web Analysis: Bayer
    • 10.4.4. Spider Web Analysis: BioNTech
    • 10.4.5. Spider Web Analysis: Eli Lilly
    • 10.4.6. Spider Web Analysis: Gilead Sciences
    • 10.4.7. Spider Web Analysis: GlaxoSmithKline
    • 10.4.8. Spider Web Analysis: Merck
    • 10.4.9. Spider Web Analysis: Moderna
    • 10.4.10. Spider Web Analysis: Novartis
    • 10.4.11. Spider Web Analysis: Novo Nordisk
    • 10.4.12. Spider Web Analysis: Pfizer
    • 10.4.13. Spider Web Analysis: Roche
    • 10.4.14. Spider Web Analysis: Sanofi
    • 10.4.15. Spider Web Analysis: Takeda
  • 10.5. Concluding Remarks

11. START-UP HEALTH INDEXING

  • 11.1. Chapter Overview
  • 11.2. Start-ups focused on mRNA Vaccine and Therapeutics
    • 11.2.1. Analysis by Location of Headquarters
  • 11.3. Benchmarking of Start-ups
  • 11.4. Startup-Health Indexing
    • 11.4.1. Analysis by Supplier Strength
    • 11.4.2. Analysis by Pipeline Maturity
    • 11.4.3. Analysis by Pipeline Strength
    • 11.4.4. Analysis by Financial Investments
    • 11.4.5. Analysis by Partnership Activity
    • 11.4.6. Start-ups Health Indexing: Roots Analysis Perspective

12. CLINICAL TRIAL ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. mRNA Vaccine and Therapeutics: Clinical Trial Analysis
    • 12.3.1. Analysis by Trial Registration Year
    • 12.3.2. Analysis by Trial Status
    • 12.3.3. Analysis by Trial Phase
    • 12.3.4. Analysis by Trial Registration Year and Trial Status
    • 12.3.5. Analysis by Trial Registration Year and Trial Phase
    • 12.3.6. Analysis by Trial Status and Trial Phase
    • 12.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
    • 12.3.8. Analysis by Study Design
    • 12.3.9. Analysis by Type of Sponsor / Collaborator
    • 12.3.10. Most Active Players: Analysis by Number of Registered Trials
    • 12.3.11. Analysis by Therapeutic Area
    • 12.3.12. Analysis by Number of Registered Trials and Geography
    • 12.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
    • 12.3.14. Analysis of Enrolled Patient Population by Geography

13. PARTNERSHIPS AND COLLABORATIONS

  • 13.1. Chapter Overview
  • 13.2. Partnership Models
  • 13.3. mRNA Vaccine and Therapeutics: Partnerships and Collaborations
    • 13.3.1. Analysis by Year of Partnership
    • 13.3.2. Analysis by Type of Partnership
    • 13.3.3. Analysis by Year and Type of Partnership
    • 13.3.4. Analysis by Therapeutic Area
    • 13.3.5. Analysis by Type of Partnership and Therapeutic Area
    • 13.3.6. Most Active Players: Analysis by Number of Partnerships
    • 13.3.7. Analysis by Geography
      • 13.3.7.1. Intercontinental and Intracontinental Agreements
      • 13.3.7.2. Local and International Agreements

14. FUNDING AND INVESTMENT ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Types of Funding
  • 14.3. mRNA Vaccine and Therapeutics: Funding and Investments
    • 14.3.1. Analysis by Year of Funding
    • 14.3.2. Analysis by Amount Invested
    • 14.3.3. Analysis by Type of Funding
    • 14.3.4. Analysis by Year and Type of Funding
    • 14.3.5. Analysis of Funding Instances and Amount Invested by Therapeutic Area
    • 14.3.6. Analysis by Geography
    • 14.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 14.3.8. Most Active Players: Analysis by Total Amount Raised
    • 14.3.9. Most Active Investors: Analysis by Number of Funding Instances
    • 14.3.10. Analysis of Amount Invested by Year and Type of Funding

15. PATENT ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Scope and Methodology
  • 15.3. mRNA Vaccine and Therapeutics: Patent Analysis
    • 15.3.1. Analysis by Type of Patent
    • 15.3.2. Analysis by Patent Publication Year
    • 15.3.3. Analysis of Granted Patents by Publication Year
    • 15.3.4. Analysis of Patent Applications by Publication Year
    • 15.3.5. Analysis of Granted Patents and Patent Applications by Publication Year
    • 15.3.6. Analysis by Publication Year and Type of Applicant
    • 15.3.7. Analysis by Patent Issuing Authority
    • 15.3.8. Analysis by Patent Age
    • 15.3.9. Analysis by CPC Symbols
    • 15.3.10. Leading Players: Analysis by Number of Patents
    • 15.3.11. Leading Inventors: Analysis by Number of Patents
  • 15.4. Patent Benchmarking Analysis
    • 15.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
  • 15.5. mRNA Vaccine and Therapeutics: Patent Valuation Analysis

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 16.1. Chapter Overview
  • 16.2. Market Drivers
  • 16.3. Market Restraints
  • 16.4. Market Opportunities
  • 16.5. Market Challenges
  • 16.6. Conclusion

17. GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Global mRNA Vaccine and Therapeutics Market, till 2035
    • 17.3.1. Scenario Analysis
      • 17.3.1.1. Conservative Scenario
      • 17.3.1.2. Optimistic Scenario
  • 17.4. Key Market Segmentations

18. mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION AREA

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035
    • 18.3.1. mRNA Vaccine and Therapeutics Market for Covid-19, till 2035
    • 18.3.2. mRNA Vaccine and Therapeutics Market for Other Indications, till 2035
  • 18.4. Data Triangulation and Validation

19. mRNA VACCINE AND THERAPEUTICS MARKET, BY TARGET DISEASE INDICATION

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035
    • 19.3.1. mRNA Vaccine and Therapeutics Market for Influenza, till 2035
    • 19.3.2. mRNA Vaccine and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035
    • 19.3.3. mRNA Vaccine and Therapeutics Market for Cytomegalovirus Disease, till 2035
  • 19.4. Data Triangulation and Validation

20. mRNA VACCINE AND THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2020, 2024 and 2035
    • 20.3.1. mRNA Vaccine and Therapeutics Market in North America, till 2035
      • 20.3.1.1. mRNA Vaccine and Therapeutics Market in the US, till 2035
      • 20.3.1.2. mRNA Vaccine and Therapeutics Market in Canada, till 2035
    • 20.3.2. mRNA Vaccine and Therapeutics Market in Europe, till 2035
      • 20.3.2.1. mRNA Vaccine and Therapeutics Market in Germany, till 2035
      • 20.3.2.2. mRNA Vaccine and Therapeutics Market in the UK, till 2035
      • 20.3.2.3. mRNA Vaccine and Therapeutics Market in France, till 2035
      • 20.3.2.4. mRNA Vaccine and Therapeutics Market in Italy, till 2035
      • 20.3.2.5. mRNA Vaccine and Therapeutics Market in Spain, till 2035
      • 20.3.2.6. mRNA Vaccine and Therapeutics Market in Belgium, till 2035
    • 20.3.3. mRNA Vaccine and Therapeutics Market in Asia-Pacific, till 2035
      • 20.3.3.1. mRNA Vaccine and Therapeutics Market in China, till 2035
      • 20.3.3.2. mRNA Vaccine and Therapeutics Market in India, till 2035
      • 20.3.3.3. mRNA Vaccine and Therapeutics Market in Japan, till 2035
      • 20.3.3.4. mRNA Vaccine and Therapeutics Market in Philippines, till 2035
      • 20.3.3.5. mRNA Vaccine and Therapeutics Market in Australia, till 2035
    • 20.3.4. mRNA Vaccine and Therapeutics Market in Latin America, till 2035
      • 20.3.4.1. mRNA Vaccine and Therapeutics Market in Brazil, till 2035
    • 20.3.5. mRNA Vaccine and Therapeutics Market in Rest of the World, till 2035
  • 20.4. Data Triangulation and Validation

21. CONCLUSION

List of Tables

  • Table 6.1 mRNA Vaccine and Therapeutics: Overall Market Landscape
  • Table 6.2 mRNA Vaccine and Therapeutics: Information on Type of Delivery System
  • Table 6.3 mRNA Vaccine and Therapeutics: Information on Type of Molecule Encoded
  • Table 6.4 mRNA Vaccine and Therapeutics: Information on Route of Administration
  • Table 7.1 mRNA Vaccine and Therapeutics Developers: List of Companies
  • Table 9.1 mRNA Vaccine and Therapeutics Developers: List of Companies Profiled
  • Table 9.2 Arcturus Therapeutics: Company Overview
  • Table 9.3 Arcturus Therapeutics: Pipeline Overview
  • Table 9.4 Arcturus Therapeutics: Recent Developments and Future Outlook
  • Table 9.5 BioNTech: Company Overview
  • Table 9.6 BioNTech: Pipeline Overview
  • Table 9.7 BioNTech: Recent Developments and Future Outlook
  • Table 9.8 CureVac: Company Overview
  • Table 9.9 CureVac: Pipeline Overview
  • Table 9.10 CureVac: Recent Developments and Future Outlook
  • Table 9.11 Ethris: Company Overview
  • Table 9.12 Ethris: Pipeline Overview
  • Table 9.13 Ethris: Recent Developments and Future Outlook
  • Table 9.14 Immorna: Company Overview
  • Table 9.15 Immorna: Cancer Biomarker Testing Solutions Portfolio
  • Table 9.16 Immorna: Recent Developments and Future Outlook
  • Table 9.17 Moderna: Company Overview
  • Table 9.18 Moderna: Pipeline Overview
  • Table 9.19 Moderna: Recent Developments and Future Outlook
  • Table 9.20 Providence Therapeutics: Company Overview
  • Table 9.21 Providence Therapeutics: Pipeline Overview
  • Table 9.22 Providence Therapeutics: Recent Developments and Future Outlook
  • Table 9.23 Suzhou Abogen Biosciences: Company Overview
  • Table 9.24 Suzhou Abogen Biosciences: Pipeline Overview
  • Table 9.25 Gennova Biopharmaceuticals: Company Overview
  • Table 9.26 Gennova Biopharmaceuticals: Pipeline Overview
  • Table 9.27 Innovac Therapeutics: Company Overview
  • Table 9.28 Innovac Therapeutics: Pipeline Overview
  • Table 9.29 Kernal Biologics: Company Overview
  • Table 9.30 Kernal Biologics: Pipeline Overview
  • Table 9.31 Pantherna Therapeutics: Company Overview
  • Table 9.32 Pantherna Therapeutics: Pipeline Overview
  • Table 9.33 pHion Therapeutics: Company Overview
  • Table 9.34 pHion Therapeutics: Pipeline Overview
  • Table 9.35 Recode Therapeutics: Company Overview
  • Table 9.36 Recode Therapeutics: Pipeline Overview
  • Table 9.37 Rejuvenation Technologies: Company Overview
  • Table 9.38 Rejuvenation Technologies: Pipeline Overview
  • Table 9.39 RNACure: Company Overview
  • Table 9.40 RNACure: Pipeline Overview
  • Table 9.41 RNAimmune: Company Overview
  • Table 9.42 RNAimmune: Pipeline Overview
  • Table 9.43 Strand Therapeutics: Company Overview
  • Table 9.44 Strand Therapeutics: Pipeline Overview
  • Table 9.45 Turn Biotechnologies: Company Overview
  • Table 9.46 Turn Biotechnologies: Pipeline Overview
  • Table 9.47 Walvax: Company Overview
  • Table 9.48 Walvax: Pipeline Overview
  • Table 9.49 Ziphius Vaccines: Company Overview
  • Table 9.50 Ziphius Vaccines: Pipeline Overview
  • Table 11.1 mRNA Vaccine and Therapeutics Start-ups: Information on Location of Headquarters
  • Table 13.1 mRNA Vaccine and Therapeutics: List of Partnerships and Collaborations
  • Table 13.2 mRNA Vaccine and Therapeutics: Information on Type of Agreement (Country and Region), since 2013
  • Table 14.1 mRNA Vaccine and Therapeutics: List of Funding and Investments
  • Table 15.1 Patent Analysis: Top CPC Sections
  • Table 15.2 Patent Analysis: Top CPC Symbols
  • Table 15.3 Patent Analysis: Top CPC
  • Table 15.4 Patent Portfolio: Summary of Benchmarking Analysis
  • Table 15.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 15.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 17.1 mRNA Vaccine and Therapeutics: Expected Launch Year of Advance Stage Drug Candidates
  • Table 22.1 eTheRNA: Key Highlights
  • Table 23.1 mRNA Vaccine and Therapeutics: Distribution by Phase of Development
  • Table 23.2 mRNA Vaccine and Therapeutics: Distribution by Type of Drug Candidate
  • Table 23.3 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area
  • Table 23.4 mRNA Vaccine and Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Table 23.5 mRNA Vaccine and Therapeutics: Distribution by Type of Delivery System Used
  • Table 23.6 mRNA Vaccine and Therapeutics: Distribution by Type of Molecule Encoded
  • Table 23.7 mRNA Vaccine and Therapeutics: Distribution by Route of Administration
  • Table 23.8 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area and Route of Administration
  • Table 23.9 mRNA Vaccine and Therapeutics Developers: Distribution by Year of Establishment
  • Table 23.10 mRNA Vaccine and Therapeutics Developers: Distribution by Company Size
  • Table 23.11 mRNA Vaccine and Therapeutics Developers: Distribution by Location of Headquarters
  • Table 23.12 Key Players: Distribution by Number of Drug Candidates
  • Table 23.13 Key Players: Distribution by Phase of Development
  • Table 23.14 Key Players: Distribution by Therapeutic Area
  • Table 23.15 Startup-Health Indexing: Distribution by Location of Headquarters
  • Table 23.16 Startup-Health Indexing: Distribution by Supplier Strength
  • Table 23.17 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Table 23.18 Startup-Health Indexing: Distribution by Pipeline Strength
  • Table 23.19 Startup-Health Indexing: Distribution by Financial Investments
  • Table 23.20 Startup-Health Indexing: Distribution by Partnership Activity
  • Table 23.21 Clinical Trial Analysis: Distribution by Trial Registration Year, since 2017
  • Table 23.22 Clinical Trial Analysis: Distribution by Trial Status
  • Table 23.23 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 23.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 23.25 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
  • Table 23.26 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Table 23.27 Clinical Trial Analysis: Distribution by Study Design
  • Table 23.28 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 23.29 Most Active Players: Distribution by Number of Registered Trials
  • Table 23.30 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 23.31 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
  • Table 23.32 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
  • Table 23.33 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Table 23.34 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2013
  • Table 23.35 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 23.36 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 23.37 Most Active Players: Distribution by Number of Partnerships
  • Table 23.38 Partnerships and Collaborations: Local and International Agreements
  • Table 23.39 Funding and Investment Analysis: Cumulative Year-wise Trend, since 2015
  • Table 23.40 Funding and Investment Analysis: Distribution of Amount Invested, since 2015 (USD Million)
  • Table 23.41 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
  • Table 23.42 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 23.43 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Table 23.44 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Therapeutic Area
  • Table 23.45 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Region
  • Table 23.46 Funding and Investment Analysis: Distribution of Funding Instances by Country
  • Table 23.47 Most Active Players: Distribution by Number of Funding Instances
  • Table 23.48 Most Active Players: Distribution by Total Amount Raised (USD Million)
  • Table 23.49 Most Active Investors: Distribution by Number of Funding Instances
  • Table 23.50 Patent Analysis: Distribution by Type of Patent
  • Table 23.51 Patent Analysis: Cumulative Distribution by Patent Publication Year, since 2016
  • Table 23.52 Patent Analysis: Distribution of Granted Patents by Publication Year, since 2016
  • Table 23.53 Patent Analysis: Distribution of Patent Applications by Publication Year, since 2016
  • Table 23.54 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year, since 2016
  • Table 23.55 Patent Analysis: Distribution of Patents by Publication Year and Type of Applicant, since 2016
  • Table 23.56 Patent Analysis: Distribution by Patent Issuing Authority
  • Table 23.57 Patent Analysis: Distribution by Patent Age
  • Table 23.58 Patent Analysis: Leading Industry Players
  • Table 23.59 Patent Analysis: Leading Non-Industry Players
  • Table 23.60 Leading Inventors: Distribution by Number of Patents
  • Table 23.61 Patent Analysis: Valuation Analysis
  • Table 23.62 Global mRNA Therapeutics and Vaccines Market, Historical Trends, since 2020 (USD Million)
  • Table 23.63 Global mRNA Therapeutics and Vaccines Market, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.64 mRNA Therapeutics and Vaccines Market: Distribution by Application Area, 2020, 2026 and 2035 (USD Million)
  • Table 23.65 mRNA Therapeutics and Vaccines Market for Covid-19, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.66 mRNA Therapeutics and Vaccines Market for Other Indications, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.67 mRNA Therapeutics and Vaccines Market: Distribution by Target Disease Indication, 2026, 2030 and 2035 (USD Million)
  • Table 23.68 mRNA Therapeutics and Vaccines Market for Influenza, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.69 mRNA Therapeutics and Vaccines Market for Respiratory Syncytial Virus Infection, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.70 mRNA Therapeutics and Vaccines Market for Cytomegalovirus Disease, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.71 mRNA Therapeutics and Vaccines Market: Distribution by Geographical Regions, 2020, 2024 and 2035 (USD Million)
  • Table 23.72 mRNA Therapeutics and Vaccines Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.73 mRNA Therapeutics and Vaccines Market in the US, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.74 mRNA Therapeutics and Vaccines Market in Canada, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.75 mRNA Therapeutics and Vaccines Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.76 mRNA Therapeutics and Vaccines Market in Germany, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.77 mRNA Therapeutics and Vaccines Market in the UK, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.78 mRNA Therapeutics and Vaccines Market in France, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.79 mRNA Therapeutics and Vaccines Market in Italy, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.80 mRNA Therapeutics and Vaccines Market in Spain, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.81 mRNA Therapeutics and Vaccines Market in Belgium, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.82 mRNA Therapeutics and Vaccines Market in Asia-Pacific, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.83 mRNA Therapeutics and Vaccines Market in China, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.84 mRNA Therapeutics and Vaccines Market in India, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.85 mRNA Therapeutics and Vaccines Market in Japan, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.86 mRNA Therapeutics and Vaccines Market in Philippines, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.87 mRNA Therapeutics and Vaccines Market in Australia, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.88 mRNA Therapeutics and Vaccines Market in Latin America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.89 mRNA Therapeutics and Vaccines Market in Brazil, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 23.90 mRNA Therapeutics and Vaccines Market in Rest of the World, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Secondary Research: Data Sources
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Market Landscape
  • Figure 4.2 Executive Summary: Clinical Trial Analysis
  • Figure 4.3 Executive Summary: Partnerships and Collaborations
  • Figure 4.4 Executive Summary: Funding and Investment Analysis
  • Figure 4.5 Executive Summary: Patent Analysis
  • Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 5.1 Historical Evolution of mRNA
  • Figure 5.2 Key Applications of mRNA Therapeutics
  • Figure 6.1 mRNA Vaccine and Therapeutics: Distribution by Phase of Development
  • Figure 6.2 mRNA Vaccine and Therapeutics: Distribution by Type of Drug Candidate
  • Figure 6.3 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area
  • Figure 6.4 mRNA Vaccine and Therapeutics: Distribution by Phase of Development and Therapeutic Area
  • Figure 6.5 mRNA Vaccine and Therapeutics: Distribution by Type of Delivery System
  • Figure 6.6 mRNA Vaccine and Therapeutics: Distribution by Type of Molecule Encoded
  • Figure 6.7 mRNA Vaccine and Therapeutics: Distribution by Route of Administration
  • Figure 6.8 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area and Route of Administration
  • Figure 6.9 mRNA Vaccine and Therapeutics: Distribution by Phase of Development, Therapeutic Area and Route of Administration
  • Figure 7.1 mRNA Vaccine and Therapeutics Developers: Distribution by Year of Establishment
  • Figure 7.2 mRNA Vaccine and Therapeutics Developers: Distribution by Company Size
  • Figure 7.3 mRNA Vaccine and Therapeutics Developers: Distribution by Location of Headquarters
  • Figure 7.4 Key Players: Distribution by Number of Drug Candidates
  • Figure 7.5 Key Players: Distribution by Phase of Development
  • Figure 7.6 Key Players: Distribution by Therapeutic Area
  • Figure 8.1 Company Competitiveness Analysis: mRNA Vaccine and Therapeutics Developers based in North America
  • Figure 8.2 Company Competitiveness Analysis: mRNA Vaccine and Therapeutics Developers based in Europe
  • Figure 8.3 Company Competitiveness Analysis: mRNA Vaccine and Therapeutics Developers based in Asia-Pacific and Rest of the World
  • Figure 10.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies
  • Figure 10.2 Big Pharma Players: Distribution by Portfolio Diversity
  • Figure 10.3 Big Pharma Players: Distribution by Phase of Development
  • Figure 10.4 Big Pharma Players: Distribution by Target Therapeutic Area
  • Figure 10.5 Spider Web Analysis: Amgen
  • Figure 10.6 Spider Web Analysis: AstraZeneca
  • Figure 10.7 Spider Web Analysis: Bayer
  • Figure 10.8 Spider Web Analysis: BioNTech
  • Figure 10.9 Spider Web Analysis: Eli Lilly
  • Figure 10.10 Spider Web Analysis: Gilead Sciences
  • Figure 10.11 Spider Web Analysis: GlaxoSmithKline
  • Figure 10.12 Spider Web Analysis: Merck
  • Figure 10.13 Spider Web Analysis: Moderna
  • Figure 10.14 Spider Web Analysis: Novartis
  • Figure 10.15 Spider Web Analysis: Novo Nordisk
  • Figure 10.16 Spider Web Analysis: Pfizer
  • Figure 10.17 Spider Web Analysis: Roche
  • Figure 10.18 Spider Web Analysis: Sanofi
  • Figure 10.19 Spider Web Analysis: Takeda
  • Figure 11.1 Startup-Health Indexing: Distribution by Location of Headquarters
  • Figure 11.2 Startup-Health Indexing: Distribution by Supplier Strength
  • Figure 11.3 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Figure 11.4 Startup-Health Indexing: Distribution by Pipeline Strength
  • Figure 11.5 Startup-Health Indexing: Distribution by Financial Investments
  • Figure 11.6 Startup-Health Indexing: Distribution by Partnership Activity
  • Figure 11.7 Start-up Health Indexing: Roots Analysis Perspective
  • Figure 11.8 Start-up Health Indexing: Leading Companies
  • Figure 12.1 Clinical Trial Analysis: Distribution by Trial Registration Year, since 2017
  • Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 12.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 12.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
  • Figure 12.6 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
  • Figure 12.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Figure 12.8 Clinical Trial Analysis: Distribution by Study Design
  • Figure 12.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 12.10 Most Active Players: Distribution by Number of Registered Trials
  • Figure 12.11 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 12.12 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
  • Figure 12.13 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
  • Figure 12.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
  • Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2013
  • Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 13.4 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 13.5 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Figure 13.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 13.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 13.8 Partnerships and Collaborations: Local and International Agreements
  • Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, since 2013
  • Figure 14.2 Funding and Investment Analysis: Distribution of Amount Invested, since 2013 (USD Million)
  • Figure 14.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
  • Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 14.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Figure 14.6 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Therapeutic Area
  • Figure 14.7 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Region
  • Figure 14.8 Funding and Investment Analysis: Distribution of Funding Instances by Country
  • Figure 14.9 Most Active Players: Distribution by Number of Funding Instances
  • Figure 14.10 Most Active Players: Distribution by Total Amount Raised (USD Million)
  • Figure 14.11 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 14.12 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding
  • Figure 15.1 Patent Analysis: Distribution by Type of Patent
  • Figure 15.2 Patent Analysis: Distribution by Patent Publication Year, since 2016
  • Figure 15.3 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, since 2016
  • Figure 15.4 Patent Analysis: Cumulative Distribution of Patent Applications by Publication Year, since 2016
  • Figure 15.5 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year, since 2016
  • Figure 15.6 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, since 2016
  • Figure 15.7 Patent Analysis: Distribution by Patent Issuing Authority
  • Figure 15.8 Patent Analysis: Distribution by Patent Age
  • Figure 15.9 Patent Analysis: Distribution by CPC Sections
  • Figure 15.10 Patent Analysis: Leading Industry Players
  • Figure 15.11 Patent Analysis: Leading Non-Industry Players
  • Figure 15.12 Leading Inventors: Distribution by Number of Patents
  • Figure 15.13 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Figure 15.14 Patent Analysis: Patent Valuation
  • Figure 16.1 mRNA Vaccine and Therapeutics: Market Drivers
  • Figure 16.2 mRNA Vaccine and Therapeutics: Market Restraints
  • Figure 16.3 mRNA Vaccine and Therapeutics: Market Opportunities
  • Figure 16.4 mRNA Vaccine and Therapeutics: Market Challenges
  • Figure 17.1 Global mRNA Vaccine and Therapeutics Market, till 2035 (USD Million)
  • Figure 17.2 Global mRNA Vaccine and Therapeutics Market, till 2035: Conservative Scenario (USD Million)
  • Figure 17.3 Global mRNA Vaccine and Therapeutics Market, till 2035: Optimistic Scenario (USD Million)
  • Figure 18.1 mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035
  • Figure 18.2 mRNA Vaccine and Therapeutics Market for Covid-19, till 2035 (USD Million)
  • Figure 18.3 mRNA Vaccine and Therapeutics Market for Other Indications, till 2035 (USD Million)
  • Figure 19.1 mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035
  • Figure 19.2 mRNA Vaccine and Therapeutics Market for Influenza, till 2035 (USD Million)
  • Figure 19.3 mRNA Vaccine and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035 (USD Million)
  • Figure 19.4 mRNA Vaccine and Therapeutics Market for Cytomegalovirus Disease, till 2035 (USD Million)
  • Figure 20.1 mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2020, 2024 and 2035
  • Figure 20.2 mRNA Vaccine and Therapeutics Market in North America, till 2035 (USD Million)
  • Figure 20.3 mRNA Vaccine and Therapeutics Market in the US, till 2035 (USD Million)
  • Figure 20.4 mRNA Vaccine and Therapeutics Market in Canada, till 2035 (USD Million)
  • Figure 20.5 mRNA Vaccine and Therapeutics Market in Europe, till 2035 (USD Million)
  • Figure 20.6 mRNA Vaccine and Therapeutics Market in Germany, till 2035 (USD Million)
  • Figure 20.7 mRNA Vaccine and Therapeutics Market in the UK, till 2035 (USD Million)
  • Figure 20.8 mRNA Vaccine and Therapeutics Market in France, till 2035 (USD Million)
  • Figure 20.9 mRNA Vaccine and Therapeutics Market in Italy, till 2035 (USD Million)
  • Figure 20.10 mRNA Vaccine and Therapeutics Market in Spain, till 2035 (USD Million)
  • Figure 20.11 mRNA Vaccine and Therapeutics Market in Belgium, till 2035 (USD Million)
  • Figure 20.12 mRNA Vaccine and Therapeutics Market in Aisa-Pacific, till 2035 (USD Million)
  • Figure 20.13 mRNA Vaccine and Therapeutics Market in China, till 2035 (USD Million)
  • Figure 20.14 mRNA Vaccine and Therapeutics Market in India, till 2035 (USD Million)
  • Figure 20.15 mRNA Vaccine and Therapeutics Market in Japan, till 2035 (USD Million)
  • Figure 20.16 mRNA Vaccine and Therapeutics Market in Philippines, till 2035 (USD Million)
  • Figure 20.17 mRNA Vaccine and Therapeutics Market in Australia, till 2035 (USD Million)
  • Figure 20.18 mRNA Vaccine and Therapeutics Market in Latin America, till 2035 (USD Million)
  • Figure 20.19 mRNA Vaccine and Therapeutics Market in Brazil, till 2035 (USD Million)
  • Figure 20.20 mRNA Vaccine and Therapeutics Market in Rest of the World, till 2035 (USD Million)
  • Figure 21.1 Concluding Remarks: Overall Market Landscape
  • Figure 21.2 Concluding Remarks: Partnerships and Collaborations
  • Figure 21.3 Concluding Remarks: Funding and Investment Analysis
  • Figure 21.4 Concluding Remarks: Clinical Trial Analysis
  • Figure 21.5 Concluding Remarks: Patent Analysis
  • Figure 21.6 Concluding Remarks: Market Forecast and Opportunity Analysis